-
Antibody generation and immunoassay development in diverse formats for pyrimethanil specific and sensitive analysis.
The Analyst 20121207
-
2-Anilino-4-(benzimidazol-2-yl)pyrimidines--a multikinase inhibitor scaffold with antiproliferative activity toward cancer cell lines.
European journal of medicinal chemistry 20120701
-
Immunoreagent generation and competitive assay development for cyprodinil analysis.
Journal of agricultural and food chemistry 20120516
-
Autocrine PDGF stimulation in malignancies.
Upsala journal of medical sciences 20120501
-
Determination of farm workers' exposure to pesticides by hair analysis.
Toxicology letters 20120425
-
Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.
Photodermatology, photoimmunology & photomedicine 20120201
-
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
Journal of medicinal chemistry 20120112
-
3D-QSAR studies of JNK1 inhibitors utilizing various alignment methods.
Chemical biology & drug design 20120101
-
Production and characterization of antifungal compounds produced by Lactobacillus plantarum IMAU10014.
PloS one 20120101
-
Role of STAT3 in Transformation and Drug Resistance in CML.
Frontiers in oncology 20120101
-
Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.
PloS one 20120101
-
Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents.
ISRN oncology 20120101
-
Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
Bioorganic & medicinal chemistry letters 20111201
-
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
European journal of haematology 20111101
-
Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile.
Neuro-oncology 20111101
-
4-Nitro-benzoic acid-N-(pyrimidin-2-yl)aniline (1/1).
Acta crystallographica. Section E, Structure reports online 20111101
-
Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase.
Journal of the American Chemical Society 20111005
-
Selectivity of kinase inhibitor fragments.
Journal of medicinal chemistry 20110728
-
Crystal structures of ABL-related gene (ABL2) in complex with imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole carbothioamide class.
Journal of medicinal chemistry 20110414
-
Effect of anilinopyrimidine resistance on aflatoxin production and fitness parameters in Aspergillus parasiticus Speare.
International journal of food microbiology 20110330
-
Structure-activity relationship of 4(5)-aryl-2-amino-1H-imidazoles, N1-substituted 2-aminoimidazoles and imidazo[1,2-a]pyrimidinium salts as inhibitors of biofilm formation by Salmonella typhimurium and Pseudomonas aeruginosa.
Journal of medicinal chemistry 20110127
-
Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.
Cancer management and research 20110101
-
Nephrogenic systemic fibrosis: current concepts.
Indian journal of dermatology 20110101
-
Cell-intrinsic NF-κB activation is critical for the development of natural regulatory T cells in mice.
PloS one 20110101
-
Simultaneous visualization of both signaling cascade activity and end-point gene expression in single cells.
PloS one 20110101
-
Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.
PloS one 20110101
-
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.
Clinical Medicine Insights. Oncology 20110101
-
2D QSAR Studies of Several Potent Aminopyridine, Anilinopyrimidine and Pyridine Carboxamide-based JNK Inhibitors.
Indian journal of pharmaceutical sciences 20110101
-
Probing the probes: fitness factors for small molecule tools.
Chemistry & biology 20100625
-
N-(5-Amino-2-methyl-phen-yl)-4-(3-pyri-dyl)-pyrimidin-2-amine.
Acta crystallographica. Section E, Structure reports online 20100201
-
Imatinibium dipicrate.
Acta crystallographica. Section E, Structure reports online 20100201
-
Progress on antiangiogenic therapy for patients with malignant glioma.
Journal of oncology 20100101
-
Targeting lymphatic vessel functions through tyrosine kinases.
Journal of angiogenesis research 20100101
-
Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment.
Therapeutics and clinical risk management 20100101
-
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.
BMC blood disorders 20100101
-
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.
Biologics : targets & therapy 20100101
-
Studies of Antimicrobial Activities of some 4-Thiazolidinone Fused Pyrimidines, [1,5]-Benzodiazepines and their Oxygen Substituted Hydroxylamine Derivatives.
Indian journal of pharmaceutical sciences 20100101
-
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
British journal of cancer 20091215
-
Fungicide-driven evolution and molecular basis of multidrug resistance in field populations of the grey mould fungus Botrytis cinerea.
PLoS pathogens 20091201
-
Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells.
Molecules (Basel, Switzerland) 20091019
-
Design, synthesis and fungicidal activity of novel strobilurin analogues containing substituted N-phenylpyrimidin-2-amines.
Natural product communications 20090901
-
Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen.
Journal of neuro-oncology 20090701
-
Anaplastic lymphoma kinase: signalling in development and disease.
The Biochemical journal 20090615
-
N-(Pyrimidin-2-yl)aniline.
Acta crystallographica. Section E, Structure reports online 20090401
-
Kinase inhibitors for the treatment of inflammatory and autoimmune disorders.
Purinergic signalling 20090301
-
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).
BMC structural biology 20090101
-
PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.
PloS one 20090101
-
Dasatinib in chronic myeloid leukemia: a review.
Therapeutics and clinical risk management 20090101
-
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
PloS one 20090101
-
Current available therapies and future directions in the treatment of malignant gliomas.
Biologics : targets & therapy 20090101
-
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
PloS one 20090101
-
Degradation of pesticide residues in vineyard effluents by activated sludge treatment.
Water science and technology : a journal of the International Association on Water Pollution Research 20090101
-
Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).
PloS one 20090101
-
Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death.
PloS one 20090101
-
Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs).
OncoTargets and therapy 20090101
-
Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
Bioorganic & medicinal chemistry letters 20081201
-
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.
Future oncology (London, England) 20081001
-
Phase II trial of imatinib mesylate in patients with metastatic melanoma.
British journal of cancer 20080902
-
Evaluation of anilinopyrimidine and other fungicides for control of grey mould (Botrytis cinerea) in container-grown Calluna vulgaris.
Pest management science 20080701
-
Targeting IKK2 by pharmacological inhibitor AS602868 prevents excitotoxic injury to neurons and oligodendrocytes.
Journal of neural transmission (Vienna, Austria : 1996) 20080501
-
Stability and fitness of anilinopyrimidine-resistant strains of Botrytis cinerea.
Phytopathology 20080401
-
Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1.
Biochemistry 20080311
-
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate.
Therapeutics and clinical risk management 20080201
-
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).
Therapeutics and clinical risk management 20080201
-
Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.
British journal of cancer 20080129
-
Na+/H+ exchanger regulatory factor 1 inhibits platelet-derived growth factor signaling in breast cancer cells.
Breast cancer research : BCR 20080101
-
Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts.
British journal of cancer 20070911
-
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.
British journal of haematology 20070701
-
Reducing uncertainty in health-care resource allocation.
British journal of cancer 20070618
-
Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.
BMC pharmacology 20070101
-
Study on the sensitivity of Venturia inaequalis to anilinopyrimidine fungicides in Italy.
Communications in agricultural and applied biological sciences 20070101
-
NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor.
Analytical chemistry insights 20070101
-
Degradation of anilinopyrimidine fungicides photoinduced by iron(III)-polycarboxylate complexes.
Pest management science 20060901
-
Renal cell carcinoma and the use of sorafenib.
Therapeutics and clinical risk management 20060301
-
Molecular research directions in the management of gastrointestinal stromal tumors.
Current treatment options in oncology 20051101
-
Novel and efficient access to phenylamino-pyrimidine type protein kinase C inhibitors utilizing a Negishi cross-coupling strategy.
The Journal of organic chemistry 20050624
-
Additive apoptotic effect of STI571 with the cytoprotective agent amifostine in K-562 cell line.
Cancer chemotherapy and pharmacology 20050601
-
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
British journal of cancer 20050523
-
Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
Chemico-biological interactions 20050415
-
EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head.
PLoS medicine 20050301
-
A genome-wide overexpression screen in yeast for small-molecule target identification.
Chemistry & biology 20050101
-
Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase.
Bioorganic & medicinal chemistry letters 20041101
-
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
British journal of cancer 20041101
-
Imatinib-mesylate blocks recombinant T-type calcium channels expressed in human embryonic kidney-293 cells by a protein tyrosine kinase-independent mechanism.
The Journal of pharmacology and experimental therapeutics 20040401
-
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Cancer research 20040401
-
Changing picture of cellular drug resistance in human leukemia.
Critical reviews in oncology/hematology 20040401
-
[Gastrointestinal stromal tumors (GIST)].
Zeitschrift fur Gastroenterologie 20040401
-
Inhibition of platelet-derived growth factor signalling induces autophagy in malignant glioma cells.
British journal of cancer 20040308
-
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Journal of cancer research and clinical oncology 20040201
-
[Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20031201
-
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.
British journal of cancer 20031117
-
Resistance to imatinib (Glivec): update on clinical mechanisms.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20031001
-
[Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)].
Gan to kagaku ryoho. Cancer & chemotherapy 20030801
-
The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia.
Hematological oncology 20030601
-
Anilinopyrimidines as novel antituberculosis agents.
Bioorganic & medicinal chemistry letters 20030519
-
Is there a cloud in the silver lining for imatinib?
British journal of cancer 20030407
-
Field relevance of a synergistic effect observed in the laboratory between an EBI fungicide and a chloronicotinyl insecticide in the honeybee (Apis mellifera L, Hymenoptera).
Pest management science 20030301
-
Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Drugs 20030101
-
Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
In vivo (Athens, Greece) 20030101
-
Effects of STI571 (gleevec) on pancreatic cancer cell growth.
Molecular cancer 20030101
-
The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.
British journal of cancer 20020506
-
Oral lichenoid reaction to imatinib (STI 571, Gleevec).
Dermatology (Basel, Switzerland) 20020101
-
Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
In vivo (Athens, Greece) 20020101
-
Tyrosine kinase inhibitors: from rational design to clinical trials.
Medicinal research reviews 20011101
-
[Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
Bulletin du cancer 20010701
-
Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha.
Blood 20010515
-
The ABC transporter BcatrB from Botrytis cinerea is a determinant of the activity of the phenylpyrrole fungicide fludioxonil.
Pest management science 20010501
